Phase Ib/II Study of Enzalutamide With Venetoclax (ABT-199) in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Phase of Trial: Phase I/II
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Enzalutamide (Primary) ; Venetoclax (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Dec 2019 Planned End Date changed from 1 Sep 2022 to 7 Jun 2023.
- 02 Dec 2019 Planned primary completion date changed from 5 Sep 2021 to 7 Jun 2022.
- 19 Jun 2019 Status changed from not yet recruiting to recruiting.